Literatur
-
1
Andrew P.
Diastolic heart failure demystified.
Chest.
2003;
124
744-753
-
2
Beuckelmann D J, Nabauer M, Erdmann E.
Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure.
Circulation.
1992;
85
1046-1055
-
3
Boknik P, Neumann J, Kaspareit G. et al .
Mechanisms of the contractile effects of levosimendan in the mammalian heart.
J Pharmacol Exp Ther.
1997;
280
277-283
-
4
Brixius K, Pietsch M, Hoischen S, Muller-Ehmsen J, Schwinger R HG.
Effect of inotropic interventions on contraction and Ca2+ transients in the human heart.
J Appl Physiol.
1997;
83
652-660
-
5
Brixius K, Reicke S, Schwinger R HG.
Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium.
Am J Physiol.
2002;
282
H131-H137
-
6
Cleland J G, Ghosh J, Freemantle N. et al .
Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure.
Eur J Heart Fail.
2004;
6
501-508
-
7
Du T oit EF, Muller C A, McCarthy J, Opie L H.
Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart.
J Pharmacol Exp Ther.
1999;
290
505-514
-
8
Edes I, Kiss E, Kitada Y. et al .
Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart.
Circ Res.
1995;
77
107-113
-
9
Endoh M.
Mechanism of action of Ca2+ sensitizers-update 2001.
Cardiovasc Drugs Ther.
2001;
15
397-403
-
10
Felker G M, Benza R L, Chandler A B. et al .
Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study.
J Am Coll Cardiol.
2003;
41
997-1003
-
11
Follath F.
Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Ital Heart J.
2003;
4
(Suppl 2)
34S-38S
-
12
Follath F, Cleland J G, Just H. et al .
Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.
Lancet.
2002;
360
196-202
-
13
Gruhn N, Nielsen-Kudsk J E, Theilgaard S. et al .
Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties.
J Cardiovasc Pharmacol.
1998;
31
741-749
-
14
Hagemeijer F, Brand H J, van Mechelen R.
Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Am J Cardiol.
1989;
63
571-576
-
15
Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden I B.
Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan.
J Mol Cell Cardiol.
1995;
27
1859-1866
-
16
Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier L S, Just H.
Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium.
Circulation.
1998;
98
2141-2147
-
17
Hiro J, Hiro T, Reid C L, Ebrahimi R, Matsuzaki M, Gardin J M.
Safety and results of dobutamine stress echocardiography in women versus men and in patients older and younger than 75 years of age.
Am J Cardiol.
1997;
80
1014-1020
-
18
Hohnloser S H, Zehender M, Geibel A, Meinertz T, Just H.
Electrophysiologic effects of enoximone in patients with congestive heart failure.
J Cardiovasc Pharmacol.
1989;
14
(Suppl 1)
S29-S32
-
19
Holbrook M, Coker S J.
Comparison of the effects of isobutylmethylxanthine and milrinone on ischaemia-induced arrhythmias and platelet aggregation in anaesthetized rabbits.
Br J Pharmacol.
1989;
98
318-324
-
20
Holubarsch C, Hasenfuss G, Just H, Alpert N R.
Positive inotropism and myocardial energetics: influence of beta receptor agonist stimulation, phosphodiesterase inhibition, and ouabain.
Cardiovasc Res.
1994;
28
994-1002
-
21
Holubarsch C, Hasenfuss G, Thierfelder L, Heiss H W, Just H.
Vasodilation and positive inotropic effect of the phosphodiesterase inhibitor enoximone.
Z Kardiol.
1991;
80
(Suppl 4)
35-40
-
22
Korbmacher B, Sunderdiek U, Arnold G, Schulte H D, Schipke J D.
Improved ventricular function by enhancing the Ca++ sensitivity in normal and stunned myocardium of isolated rabbit hearts.
Basic Res Cardiol.
1994;
89
549-562
-
23
Labriola C, Siro-Brigiani M, Carrata F, Santangelo E, Amantea B.
Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery.
Int J Clin Pharmacol Ther.
2004;
42
204-211
-
24
Lancaster M K, Cook S J.
The effects of levosimendan on Ca2+ in guinea-pig isolated ventricular myocytes.
Eur J Pharmacol.
1997;
339
97-100
-
25
Lewis E F, Tsang S W, Fang J C. et al .
Frequency and impact of delayed decisions regarding heart transplantation on long-term outcomes in patients with advanced heart failure.
J Am Coll Cardiol.
2004;
43
794-802
-
26
Lilleberg J, Ylonen V, Lehtonen L, Toivonen L.
The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies.
Scand Cardiovasc J.
2004;
38
80-84
-
27
Lubbe W F, Podzuweit T, Opie L H.
Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors.
J Am Coll Cardiol.
1992;
19
1622-1633
-
28
Lubsen J, Just H, Hjalmarsson A C. et al .
Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.
Heart.
1996;
76
223-231
-
29
Lynch J J, Kitzen J M, Hoff P T, Lucchesi B R.
Effects of pimobendan (UD-CG 115 BS), a new positive inotropic agent, on ventricular tachycardia and ischemic ventricular fibrillation in a conscious canine model of recent myocardial infarction.
J Cardiovasc Pharmacol.
1988;
12
547-554
-
30
Matsui K, Kiyosue T, Wang J C, Dohi K, Arita M.
Effects of pimobendan on the L-type Ca2+ current and developed tension in guinea-pig ventricular myocytes and papillary muscle: comparison with IBMX, milrinone, and cilostazol.
Cardiovasc Drugs Ther.
1999;
13
105-113
-
31
Maury P, Baixas C, Roncalli J. et al .
Resumption of atrioventricular conduction by levosimendan after radiofrequency ablation of the AV node.
Pacing Clin Electrophysiol.
2004;
27
1314-1316
-
32
Moiseyev V S, Poder P, Andrejevs N. et al .
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
Eur Heart J.
2002;
23
1422-1432
-
33
Mori M, Takeuchi M, Takaoka H, Yokoyama M.
Lusitropic effects of a Ca2+ sensitization with a new cardiotonic agent, MCI-154, on diseased human hearts.
Cardiovasc Res.
1995;
30
915-922
-
34
Pataricza J, Krassoi I, Hohn J, Kun A, Papp J G.
Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery.
Cardiovasc Drugs Ther.
2003;
17
115-121
-
35
Poder P, Eha J, Sundberg S.
Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study.
J Clin Pharmacol.
2004;
44
1143-1150
-
36
Sato S, Talukder M A, Sugawara H, Sawada H, Endoh M.
Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit.
J Mol Cell Cardiol.
1998;
30
1115-1128
-
37
Shahid M, Nicholson C D.
Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30 029, milrinone and rolipram.
Naunyn Schmiedebergs Arch Pharmacol.
1990;
342
698-705
-
38
Shakar S F, Abraham W T, Gilbert E M. et al .
Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure.
J Am Coll Cardiol.
1998;
31
1336-1340
-
39
Szilagyi S, Pollesello P, Levijkovi J. et al .
The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig.
Eur J Pharmacol.
2004;
486
67-74
-
40
Takaoka H, Takeuchi M, Hata K. et al .
Beneficial effects of a Ca2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor.
Am Heart J.
1997;
133
283-289
-
41
The EPOCH Study Group .
Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure (EPOCH study).
Circ J.
2002;
66
149-157
-
42
Usta C, Puddu P E, Papalia U. et al .
Comparision of the inotropic effects of levosimendan, rolipram, and dobutamine on human atrial trabeculae.
J Cardiovasc Pharmacol.
2004;
44
622-625
-
43
Verde I, Vandecasteele G, Lezoualch F, Fischmeister R.
Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
Br J Pharmacol.
1999;
127
65-74
-
44
Westfall M V, Wahler G M, Fujino K, Solaro R J.
Electrophysiological actions of the pimobendan metabolite, UD-CG 212 Cl, in guinea pig myocardium.
J Pharmacol Exp Ther.
1992;
260
58-63
Prof. Dr. Robert H. G. Schwinger
Klinik III für Innere Medizin, Labor für Herzmuskelphysiologie und Molekulare Kardiologie
Josef-Stelzmann-Straße 9
50924 Köln
Phone: 0221/4783138
Fax: 0221/4783746
Email: Robert.Schwinger@medizin.uni-koeln.de
